Jazz Pharmaceuticals (NASDAQ: JAZZ) — Perfil da empresa, notícias e dados financeiros
Jazz Pharmaceuticals develops innovative medicines for sleep disorders and oncology, aiming to address unmet medical needs.
Jazz Pharmaceuticals
Jazz Pharmaceuticals is a global biopharmaceutical company focused on developing, commercializing, and manufacturing therapeutic products for patients with severe medical conditions, primarily in neuroscience and oncology. Headquartered in Dublin, Ireland, the company operates commercial and operational facilities in the United States, Europe, and internationally. Its neuroscience portfolio includes treatments for sleep disorders such as narcolepsy and idiopathic hypersomnia, as well as cannabinoid-based therapies for rare pediatric epilepsy syndromes. In oncology and hematology, its commercial offerings focus on acute lymphoblastic leukemia, acute myeloid leukemia, small cell lung cancer, and hepatic veno-occlusive disease.
Resumo
Operações
Produtos e/ou serviços de Jazz Pharmaceuticals
- Sleep Disorder Therapeutics: Commercialization and delivery of low-sodium oxybate oral solution formulations designed for the treatment of cataplexy and excessive daytime sleepiness in patients living with narcolepsy or idiopathic hypersomnia across North American and European healthcare markets.
- Cannabinoid Epilepsy Therapies: Production and distribution of purified plant-derived cannabidiol oral solutions indicated for controlling severe epileptic seizures associated with Lennox-Gastaut syndrome, Dravet syndrome, and tuberous sclerosis complex in pediatric and adult patient populations globally.
- Recombinant Oncology Therapies: Manufacturing and supply of recombinant erwinia asparaginase enzyme therapies developed to treat acute lymphoblastic leukemia and lymphoblastic lymphoma in patients who have developed hypersensitivity or silent inactivation to E. coli-derived asparaginase products.
- Small Cell Lung Cancer Treatments: Provision of selective transcription inhibitors formulated to treat metastatic small cell lung cancer in adult patients whose disease has progressed on or after prior platinum-based chemotherapy regimens across clinical and hospital network settings.
- Severe Veno-Occlusive Disease Therapies: Development and commercial distribution of defibrotide sodium oligonucleotide therapeutics indicated for severe hepatic veno-occlusive disease with renal or pulmonary dysfunction following hematopoietic stem cell transplantation in adult and pediatric clinical care environments.
- Liposomal Chemotherapy Formulations: Distribution of liposomal combination chemotherapy encapsulating daunorubicin and cytarabine at a fixed molar ratio, designed for the treatment of newly diagnosed therapy-related acute myeloid leukemia or acute myeloid leukemia with myelodysplasia-related changes.
equipe executiva do Jazz Pharmaceuticals
- Bruce C. CozaddCo-Founder & Chairman
- Renee D. GalaPresident, CEO & Director
- Philip L. JohnsonExecutive VP & CFO
- Neena M. PatilExecutive VP & Chief Legal Officer
- Robert IannoneExecutive VP, Chief Medical Officer and Global Head of Research & Development
- Samantha PearceExecutive VP & Chief Commercial Officer
- Patricia CarrSenior VP & Chief Accounting Officer
- John D. BluthHead of Investor Relations
- Heidi MannaExecutive VP & Chief People Officer
- Jed BlackSenior Vice President of Sleep & CNS Medicine
Últimas notícias sobre a Jazz Pharmaceuticals
Jazz Ziihera trial shows survival improvement in cancer
United StatesJazz wins FDA approval for Ziihera GEA treatment
United StatesJazz to acquire Actio for $820M, expanding epilepsy drug portfolio
United StatesJazz and AbCellera sign oncology agreement
United StatesJazz Pharmaceuticals Zepzelca misses survival endpoint in Phase 3 LAGOON lung cancer trial
United StatesFDA grants priority review for Jazz Pharmaceuticals’ Ziihera in first-line gastric cancer
United States
Principais indicadores financeiros
Resultados divulgados pela Jazz Pharmaceuticals , em USD.
- Cap. de mercado
- 13,4 bi
- Receita (TTM)
- 4,6 bi
- P/L
- 14.1
- LPA (diluído, TTM)
- 14.7
- Dividend yield
- —
- Margem de lucro
- 20.4%
| Fim do ano fiscal | Receita | Resultado operacional | Lucro líquido |
|---|---|---|---|
| 4,3 bi | 224,4 mi | -356,1 mi | |
| 4,1 bi | 716,6 mi | 560,1 mi | |
| 3,8 bi | 578,6 mi | 414,8 mi | |
| 3,7 bi | -65,5 mi | -224,1 mi |